Steck Andreas J, Erne Beat, Pareyson Davide, Sghirlanzoni Angelo, Taroni Franco, Schaeren-Wiemers Nicole
Department of Research, University Hospital Basel, Pharmacenter, Basel, Switzerland.
J Peripher Nerv Syst. 2006 Mar;11(1):61-6. doi: 10.1111/j.1085-9489.2006.00064.x.
Mutations in the gene encoding for myelin protein zero (MPZ) cause inherited demyelinating peripheral neuropathies of different severity. The molecular and cellular mechanisms by which the MPZ mutations cause neuropathy are incompletely understood. We investigated MPZ, myelin basic protein, and peripheral myelin protein 22 (PMP22) protein expression levels in a nerve biopsy of a Charcot-Marie-Tooth type 1B patient heterozygous for the Val 102 frame-shift mutation. We demonstrate by quantitative immunohistochemical as well as by Western blot analyses that MPZ expression levels were not reduced in myelin membranes, a finding that is in accordance with the mild phenotype of this patient. Our data show that heterozygous 'loss-of-function' of MPZ may not necessarily lead to reduced protein levels. In conclusion, we demonstrate that careful analysis of protein expression levels in peripheral nerve tissues provides important information with respect to the understanding of the molecular basis of these neuropathies.
编码髓磷脂蛋白零(MPZ)的基因突变会导致不同严重程度的遗传性脱髓鞘性周围神经病。MPZ突变导致神经病变的分子和细胞机制尚未完全明确。我们研究了一名1B型夏科-马里-图斯病患者的神经活检组织中MPZ、髓磷脂碱性蛋白和周围髓磷脂蛋白22(PMP22)的蛋白表达水平,该患者为Val 102移码突变的杂合子。我们通过定量免疫组织化学和蛋白质印迹分析证明,髓鞘膜中的MPZ表达水平并未降低,这一发现与该患者的轻度表型相符。我们的数据表明,MPZ的杂合性“功能丧失”不一定会导致蛋白质水平降低。总之,我们证明对外周神经组织中蛋白质表达水平进行仔细分析可为理解这些神经病变的分子基础提供重要信息。